Wird geladen...
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight into surviv...
Gespeichert in:
| Veröffentlicht in: | J Exp Clin Cancer Res |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6704566/ https://ncbi.nlm.nih.gov/pubmed/31439015 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1362-1 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|